The Market Online Video

Forge Resources eyes Yukon assays and Colombian coal revenue

Forge Resources CEO PJ Murphy discusses pending Yukon gold-copper assays, progress at its Colombian coal project and plans for future revenue.
The Market Online Video

Dune Oil targets next phase of Türkiye oil discovery

Dune Oil CEO Scott Lower discusses its 27.6-million-barrel contingent resource, upcoming seismic program and plans to advance production in Türkiye.
The Market Online Video

Leading Edge Materials advances Sweden rare earth project

Leading Edge Materials CEO Kurt Budge discusses Norra Kärr's 25-year mining concession, rare earth production potential and development plans.
The Market Online Video

New Zealand Energy targets production growth and gas storage

New Zealand Energy CEO Toby Pierce discusses production growth, Taranaki infrastructure and plans to develop Tariki into a major gas-storage facility.
The Market Online Video

Grid Metals puts rare critical metal cesium in focus

Grid Metals CEO Robin Dunbar discusses Falcon West's maiden cesium resource, strategic partnerships and the next steps for the Manitoba project.
The Market Online Video

Phenom Resources begins drilling Nevada gold target

Phenom Resources CEO Paul Cowley discusses drilling at Dobbin, SSR Mining's C$5.4 million investment and plans for its vanadium assets.
The Market Online Video

NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing

NurExone CEO Dr. Lior Shaltiel discusses U.S. exosome manufacturing, Mexico expansion, ExoPTEN and plans for a potential U.S. listing.
Open AI

OpenAI’s premium tier tests business pricing power

OpenAI’s new US$125 ChatGPT Business seats could increase recurring revenue and strengthen its case ahead of a planned IPO.
Sandisk fell sharply despite 372 per cent revenue growth as its outlook failed to meet the lofty expectations surrounding AI storage demand.

Sandisk stock slides as forecast misses lofty AI bar

Sandisk shares fell sharply despite 372 per cent revenue growth as its outlook failed to meet the lofty expectations surrounding AI storage demand.
Eli Lilly widens its lead over Novo Nordisk as demand for weight-loss drugs drives higher revenue

Weight-loss drug boom widens Lilly’s lead over Novo

Eli Lilly’s revenue surged 48 per cent as Mounjaro and Zepbound widened its commercial lead over rival Novo Nordisk.